embecta, a global medical technology company, has completed the corporate acquisition of Owen Mumford for an undisclosed amount, marking a significant consolidation in the medical device sector. Owen Mumford, established in 1952 by Ivan Owen and John Mumford, is a recognized industry leader specializing in advanced automatic injection devices for drug delivery and innovative blood sampling products, including lancets, lancing devices, and safety lancets. With 70 years of experience, Owen Mumford operates globally with offices, manufacturing sites, and distributors, headquartered in Woodstock, Oxford, UK.
This acquisition is strategically aimed at enhancing embecta's portfolio and market presence, particularly in areas critical for patient self-management and clinical care. Owen Mumford brings a diverse product range and deep expertise in developing innovative healthcare solutions for managing a variety of medical conditions. Its dedication to improving quality of life, encouraging patient compliance, preventing infection, and reducing healthcare costs aligns with broader industry objectives. The company's advanced global research, design, and manufacturing capabilities are key assets in delivering successful innovations that make a world of difference to a world of people.
The integration of Owen Mumford's established product lines and global operational footprint is expected to create substantial synergies for embecta. This move will likely strengthen embecta's position in critical areas such as drug delivery and diagnostics, expanding its reach and offering a more comprehensive suite of solutions to healthcare providers and patients worldwide. The combined entity is poised to leverage Owen Mumford's innovation pipeline and manufacturing prowess to accelerate the development and delivery of next-generation medical devices, aiming to make a greater impact on global health outcomes.